Representativeness of participants in a clinical trial for attention deficit/hyperactivity disorder? Comparison with adults from a large observational study / Craig B. H. Surman en The Journal of Clinical Psychiatry, Año 2010 - Vol. 71 - No. 12 (Diciembre)

Público ISBD [artículo]  inThe Journal of Clinical Psychiatry > Año 2010 - Vol. 71 - No. 12 (Diciembre) . - pp. 1612-1616 Título : Representativeness of participants in a clinical trial for attention deficit/hyperactivity disorder? Comparison with adults from a large observational study Tipo de documento: texto impreso Autores: Craig B. H. Surman, Autor ; Michael C. Monuteaux, Autor ; Carter R. Petty, Autor Fecha de publicación: 2022 Artículo en la página: pp. 1612-1616 Idioma : Inglés (eng) Idioma original : Inglés (eng) Palabras clave: Trastorno por déficit de atención con hiperactividad, Ensayos clínicos, Cognición, Salud mental, Ocupaciones, Clase social. Resumen: Clinical trials have demonstrated that pharmacotherapies can safely treat attention-deficit/hyperactivity disorder (ADHD) in adulthood. Eligibility criteria in these trials may significantly limit their external validity by excluding a significant portion of adults with ADHD in the general population. In particular, exclusion criteria may frequently exclude individuals with comorbid mental health conditions, which are common in the adult ADHD population. Link: ./index.php?lvl=notice_display&id=28266 [artículo] Representativeness of participants in a clinical trial for attention deficit/hyperactivity disorder? Comparison with adults from a large observational study [texto impreso] / Craig B. H. Surman, Autor ; Michael C. Monuteaux, Autor ; Carter R. Petty, Autor . - 2022 . - pp. 1612-1616. Idioma : Inglés (eng) Idioma original : Inglés (eng) in The Journal of Clinical Psychiatry > Año 2010 - Vol. 71 - No. 12 (Diciembre) . - pp. 1612-1616 Palabras clave: Trastorno por déficit de atención con hiperactividad, Ensayos clínicos, Cognición, Salud mental, Ocupaciones, Clase social. Resumen: Clinical trials have demonstrated that pharmacotherapies can safely treat attention-deficit/hyperactivity disorder (ADHD) in adulthood. Eligibility criteria in these trials may significantly limit their external validity by excluding a significant portion of adults with ADHD in the general population. In particular, exclusion criteria may frequently exclude individuals with comorbid mental health conditions, which are common in the adult ADHD population. Link: ./index.php?lvl=notice_display&id=28266

---

1 (1 - 1 / 1)